trial
as of 2026-07-01Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
NCTId NCT04531982
at a glance
Phase 3 · Completed
Enrollment 454 (actual)
Sponsored by ACADIA Pharmaceuticals Inc.
Primary completion 2024-01-25
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
454 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2020-08-05
Primary completion
2024-01-25
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Drugs
Indications
Sponsors
ACADIA Pharmaceuticals Inc.Lead Sponsor
Sites
102 total
Buenos Aires, ArgentinaBuenos Aires, ArgentinaBuenos Aires, ArgentinaCiudad Autonoma Buenos Aires, ArgentinaCiudad Autonoma Buenos Aires, ArgentinaCórdoba, ArgentinaCórdoba, ArgentinaCórdoba, ArgentinaLa Plata, ArgentinaLa Plata, ArgentinaMendoza, ArgentinaKazanlak, Bulgaria
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
454
Phase
PHASE3
Primary Completion Date
2024-01-25
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication